aTyr Pharma (LIFE) Misses Q1 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
aTyr Pharma Announces First Quarter 2021 Results and Provides Corporate Update
May 13, 2021 4:05 PM EDTData from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in the third quarter.
Preclinical data for IND candidate ATYR2810 showed anti-tumor effects in models of TNBC and NSCLC.
Bispecific antibody project with subsidiary Pangu BioPharma achieved milestones for first of two-year project.
Ended the quarter with $50.6 million in cash, cash equivalents and investments.
Company to host conference call and webcast today, May 13, at 5:00 p.m. EDT / 2:00 p.m. PDT.
SAN DIEGO, May 13,... More
